Urotensin II
UTS2peptideVasoactive peptide modulating vascular tone and inflammatory signaling in coronary disease.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationalePotent vasoconstrictor with systemic hemodynamic and inflammatory effects in atherosclerosis.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).
Type I vs non-Type I discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I35
C — non-Type-I55
A — assay feasibility66
E — evidence strength22
T1DI (composite)6
Specificity differential (R−C)-20.5
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)
Collection tube
K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Competitive/sandwich immunoassay or LC-MS/MS
Reagent / substrate
Anti-peptide antibody; or isotope-labeled internal standard (MS)
Platform
Immunoassay / LC-MS/MS
Turnaround · availability
Send-out / research · Research-grade
Literature evidence(3)
- Urotensin II in cardiovascular regulation.Vascular health and risk management · 2008 · PMID 19065995 · doi
- Dynamic Changes in Plasma Urotensin II and Its Correlation With Plaque Stability.Journal of cardiovascular pharmacology · 2021 · PMID 34173803 · doi
- Role of urotensin II in atherosclerotic cardiovascular diseases.Cardiovascular revascularization medicine : including molecular interventions · 2008 · PMID 18606380 · doi